QIAGEN N.V. announced its financial results for the third quarter of 2026, reporting net sales of $548 million, representing a 3% increase compared to Q3 2025. Operating income for the quarter rose to $132 million from $129 million in Q3 2025, while diluted EPS was $0.51 compared

QIAGEN N.V. Reports Q3 2026 Results and Suspends Outlook Pending Acquisition by EQT Private Equity

Qiagen N.V. and Crown NL Bidco B.V., a holding company controlled by the EQT XI fund, also known as EQT Private Equity, have entered into a Business Combination Agreement dated October 21, 2026. Under the agreement, the Bidder will make an all-cash voluntary public takeover offer

Qiagen N.V. Announces Public Takeover Offer from EQT Private Equity at €46.50 Per Share

QIAGEN N.V. entered into a Business Combination Agreement, dated as of October 21, 2026, with Crown NL Bidco B.V., a private limited liability company organized under the laws of The Netherlands. Under the agreement, Crown NL Bidco B.V. intends to launch a public tender offer to

QIAGEN N.V. Enters Business Combination Agreement for Planned Tender Offer by Crown NL Bidco B.V. at €46.50 Per Share

(RTTNews) - Qiagen N.V. (QGEN) on Wednesday said it has agreed to an all-cash takeover offer by EQT Private Equity at €46.50 per share, valuing the company at approximately €10.8 billion, or $12.1 billion, including $1.1 billion of net debt.

QIAGEN Agrees To EQT Takeover Offer For All Outstanding Shares At €46.50/share 

Key PointsModerna's stock has skyrocketed on exciting results from its personalized cancer vaccine.

These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?

Fintel reports that on October 6, 2026, Barclays upgraded their outlook for Qiagen N.V. (NYSE:QGEN) (LSE:0RLT) from Equal-Weight to Overweight.Qiagen N.V., headquartered in Venlo, the Netherlands, is a prominent global provider in the field of Sample to Insight solutions, primari

Barclays Upgrades Qiagen N.V. to Overweight from Equal-Weight

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Qiagen N.V. News